SEARCH

SEARCH BY CITATION

References

  • 1
    Chen YT,Scanlan MJ,Sahin U,Tureci O,Gure AO,Tsang S,Williamson B,Stockert E,Pfreundschuh M,Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 191418.
  • 2
    Boon T,Cerottini JC,Van den Eynde B,van der Bruggen P,Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994; 12: 33765.
  • 3
    van der Bruggen P,Traversari C,Chomez P,Lurquin C,De Plaen E,Van den Eynde B,Knuth A,Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 16437.
  • 4
    Gure AO,Tureci O,Sahin U,Tsang S,Scanlan MJ,Jager E,Knuth A,Pfreundschuh M,Old LJ,Chen YT. SSX: a multigene family with several members transcribed in normal testis and human cancer. Int J Cancer 1997; 72: 96571.
  • 5
    Jager D,Unkelbach M,Frei C,Bert F,Scanlan MJ,Jager E,Old LJ,Chen YT,Knuth A. Identification of tumor-restricted antigens NY-BR-1. SCP-1, and a new cancer/testis-like antigen. NW-BR-3 by serological screening of a testicular library with breast cancer serum. Cancer Immun 2002; 2: 5.
  • 6
    Hubank M,Schatz DG. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 1994; 22: 56408.
  • 7
    Brinkmann U,Vasmatzis G,Lee B,Yerushalmi N,Essand M,Pastan I. PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. Proc Natl Acad Sci USA 1998; 95: 1075762.
  • 8
    Lucas S,De Plaen E,Boon T. MAGE-B5, MAGE-B6, MAGE-C2, and MAGE-C3: four new members of the. MAGE family with tumor-specific expression. Int J Cancer 2000; 87: 5560.
  • 9
    Scanlan MJ,Altorki NK,Gure AO,Williamson B,Jungbluth A,Chen YT,Old LJ. Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene. CT9. Cancer Lett 2000; 150: 15564.
  • 10
    Jager E,Nagata Y,Gnjatic S,Wada H,Stockert E,Karbach J,Dunbar PR,Lee SY,Jungbluth A,Jager D,Arand M,Ritter G, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000; 97: 47605.
  • 11
    Choi JH,Kwon HJ,Yoon BI,Kim JH,Han SU,Joo HJ,Kim DY. Expression profile of histone deacetylase 1 in gastric cancer tissues. Jpn J Cancer Res 2001; 92: 13004.
  • 12
    Jones PA,Takai D. The role of DNA methylation in mammalian epigenetics. Science 2001; 293: 106870.
  • 13
    Jones PA,Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 41528.
  • 14
    Eden A,Gaudet F,Waghmare A,Jaenisch R. Chromosomal instability and tumors promoted by DNA hypomethylation. Science 2003; 300: 455.
  • 15
    Gaudet F,Hodgson JG,Eden A,Jackson-Grusby L,Dausman J,Gray JW,Leonhardt H,Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 2003; 300: 48992.
  • 16
    Bariol C,Suter C,Cheong K,Ku SL,Meagher A,Hawkins N,Ward R. The relationship between hypomethylation and CpG island methylation in colorectal neoplasia. Am J Pathol 2003; 162: 136171.
  • 17
    Lin CH,Hsieh SY,Sheen IS,Lee WC,Chen TC,Shyu WC,Liaw YF. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res 2001; 61: 423843.
  • 18
    Narayan A,Ji W,Zhang XY,Marrogi A,Graff JR,Baylin SB,Ehrlich M. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998; 77: 8338.
  • 19
    dos Santos NR,Torensma R,de Vries TJ,Schreurs MW,de Bruijn DR,Kater-Baats E,Ruiter DJ,Adema GJ,van Muijen GN,van Kessel AG. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res 2000; 60: 165462.
  • 20
    Missiaglia E,Donadelli M,Palmieri M,Crnogorac-Jurcevic T,Scarpa A,Lemoine NR. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene 2005; 24: 199211.
  • 21
    Momparler RL,Ayoub J. Potential of 5-aza-2′-deoxycytidine (Decitabine) a potent inhibitor of DNA methylation for therapy of advanced non-small cell lung cancer. Lung Cancer 2001; 34 (Suppl 4): S111S115.
  • 22
    Jackson-Grusby L,Laird PW,Magge SN,Moeller BJ,Jaenisch R. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci USA 1997; 94: 46815.
  • 23
    Santi DV,Norment A,Garrett CE. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 1984; 81: 69937.
  • 24
    Santini V,Kantarjian HM,Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001; 134: 57386.
  • 25
    Samlowski WE,Leachman SA,Wade M,Cassidy P,Porter-Gill P,Busby L,Wheeler R,Boucher K,Fitzpatrick F,Jones DA,Karpf AR. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005; 23: 3897905.
  • 26
    Wijermans P,Lubbert M,Verhoef G,Bosly A,Ravoet C,Andre M,Ferrant A. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 95662.
  • 27
    Kantarjian H,Issa JP,Rosenfeld CS,Bennett JM,Albitar M,DiPersio J,Klimek V,Slack J,de Castro C,Ravandi F,Helmer R,III,Shen L, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 2006; 106: 1794803.
  • 28
    Coral S,Sigalotti L,Altomonte M,Engelsberg A,Colizzi F,Cattarossi I,Maraskovsky E,Jager E,Seliger B,Maio M. 5-aza-2′-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. Clin Cancer Res 2002; 8: 26905.
  • 29
    Coral S,Sigalotti L,Gasparollo A,Cattarossi I,Visintin A,Cattelan A,Altomonte M,Maio M. Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR). J Immunother 1999; 22: 1624.
  • 30
    Schwechheimer K,Laufle RM,Schmahl W,Knodlseder M,Fischer H,Hofler H. Expression of neu/c-erbB-2 in human brain tumors. Hum Pathol 1994; 25: 77280.
  • 31
    Hiesiger EM,Hayes RL,Pierz DM,Budzilovich GN. Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol 1993; 16: 93104.
  • 32
    Chi DD,Merchant RE,Rand R,Conrad AJ,Garrison D,Turner R,Morton DL,Hoon DS. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997; 150: 214352.
  • 33
    Scarcella DL,Chow CW,Gonzales MF,Economou C,Brasseur F,Ashley DM. Expression of MAGE and GAGE in high-grade brain tumors: a potential target for specific immunotherapy and diagnostic markers. Clin Cancer Res 1999; 5: 33541.
  • 34
    Rimoldi D,Romero P,Carrel S. The human melanoma antigen-encoding gene. MAGE-1, is expressed by other tumour cells of neuroectodermal origin such as glioblastomas and neuroblastomas. Int J Cancer 1993; 54: 5278.
  • 35
    Sahin U,Koslowski M,Tureci O,Eberle T,Zwick C,Romeike B,Moringlane JR,Schwechheimer K,Feiden W,Pfreundschuh M. Expression of cancer testis genes in human brain tumors. Clin Cancer Res 2000; 6: 391622.
  • 36
    Debinski W,Gibo DM,Hulet SW,Connor JR,Gillespie GY. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 1999; 5: 98590.
  • 37
    Okano F,Storkus WJ,Chambers WH,Pollack IF,Okada H. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor α2 chain. Clin Cancer Res 2002; 8: 28515.
  • 38
    Jager E,Chen YT,Drijfhout JW,Karbach J,Ringhoffer M,Jager D,Arand M,Wada H,Noguchi Y,Stockert E,Old LJ,Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998; 187: 26570.
  • 39
    Tajima K,Obata Y,Tamaki H,Yoshida M,Chen YT,Scanlan MJ,Old LJ,Kuwano H,Takahashi T,Takahashi T,Mitsudomi T. Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer 2003; 42: 2333.
  • 40
    Herman JG,Graff JR,Myohanen S,Nelkin BD,Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93: 98216.
  • 41
    Colella S,Shen L,Baggerly KA,Issa JP,Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003; 35: 14650.
  • 42
    Gardiner-Garden M,Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196: 26182.
  • 43
    Natsume A,Ishii D,Wakabayashi T,Tsuno T,Hatano H,Mizuno M,Yoshida J. IFN-β down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res 2005; 65: 75739.
  • 44
    James SR,Link PA,Karpf AR. Epigenetic regulation of X-linked cancer/germline antigen genes by DNMT1 and DNMT3b. Oncogene 2006; 25: 697585.
  • 45
    Arai J,Yasukawa M,Ohminami H,Kakimoto M,Hasegawa A,Fujita S. Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood 2001; 97: 29037.
  • 46
    Chabot GG,Rivard GE,Momparler RL. Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-2′-deoxycytidine in rabbits and dogs. Cancer Res 1983; 43: 5927.
  • 47
    Liu G,Ying H,Zeng G,Wheeler CJ,Black KL,Yu JS. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 2004; 64: 49806.
  • 48
    Jaenisch R,Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003; 33 (Suppl): 24554.
  • 49
    Ivanova T,Vinokurova S,Petrenko A,Eshilev E,Solovyova N,Kisseljov F,Kisseljova N. Frequent hypermethylation of 5′ flanking region of TIMP-2 gene in cervical cancer. Int J Cancer 2004; 108: 8826.
  • 50
    Kim TY,Zhong S,Fields CR,Kim JH,Robertson KD. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006; 66: 7490501.
  • 51
    Ferguson AT,Vertino PM,Spitzner JR,Baylin SB,Muller MT,Davidson NE. Role of estrogen receptor gene demethylation and DNA methyltransferase.DNA adduct formation in 5-aza-2′deoxycytidine-induced cytotoxicity in human breast cancer cells. J Biol Chem 1997; 272: 322606.
  • 52
    Karpf AR,Moore BC,Ririe TO,Jones DA. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol Pharmacol 2001; 59: 7517.